News | September 11, 2024
Evonik starts operation of new spray drying facility for pharmaceutical oral excipients
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
Investment in new plant meets increasing demand for functional excipients for oral drug delivery
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
This marks the first regulatory approval worldwide for nasally-delivered epinephrine
The robotic surgery program has continually pushed the boundaries of medical technology
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Detailed data from Phase 3 ECHELON-3 study demonstrate investigational ADCETRIS regimen reduced risk of death by 37 percent compared to chemotherapy alone
Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen
Subscribe To Our Newsletter & Stay Updated
